Prostate cancer -- a few small steps, much to be done

Trump, Donald L.
April 2008
Hem/Onc Today;4/25/2008, Vol. 9 Issue 7, p3
The author reflects on the little progress made in the use of systemic treatment of high-risk, localized or early recurrent prostrate cancer. He points out its similarities in treatment approaches with breast cancer. He explains that many believe that androgen deprivation does not improve prostrate cancer survival although testing and outcomes are limited. The author cites the increasing pressure on cooperative groups to reduce their budgets as a threat to progress in cancer care.


Related Articles

  • Early prostate cancer linked to family breast cancer. Groves, Nancy // Urology Times;Jun2000, Vol. 28 Issue 6, p8 

    Details findings of a study, conducted by French researchers and presented at the American Urological Association (AUA) annual meeting, linking the development of early onset prostate cancer with a female relative's development of breast cancer. Factors attributed to the familial aggregation...

  • Intermittent androgen withdrawals as effective as continuous. Susman, Ed // Urology Times;Sep2002, Vol. 30 Issue 9, p13 

    Compares the efficacy of intermittent androgen deprivation versus continuous androgen deprivation in the treatment of advanced prostate cancer. Reduced frequency and severity of adverse events; Lower disease progression rate; Improvement of quality of life.

  • Fewer Prostate Cancer Patients Are Initiating ADT, Data Shows.  // Renal & Urology News;Feb2012, Vol. 11 Issue 2, p24 

    The article reports on the decline on the use of androgen deprivation therapy (ADT) for prostate cancer (PCa).

  • Time off IAD dwindles, reflecting pattern of failure. Carlson, Robert H. // Urology Times;Aug2000, Vol. 28 Issue 8, p14 

    Focuses on the effects of intermittent androgen deprivation (IAD) intervals during off-treatment of cancer patients based on research at the University of California. Use of IAD during intervention for advanced prostate cancer; Characterization of ultimate pattern of failure during treatment;...

  • Professionals wary of shark cartilage cures.  // Nutrition Health Review: The Consumer's Medical Journal;1993, Issue 66, p8 

    Discusses the beneficial effects of powdered shark cartilage enemas in the treatment of breast and prostate cancer as reported on the television program `60 Minutes,' by Cuban researchers. William Lane's book; Skepticism regarding the validity of the news report.

  • Prostate protein turns up in women's tumours. Epstein, Helen // New Scientist;4/15/95, Vol. 146 Issue 1973, p16 

    Reports that the protein called prostate-specific antigen (PSA), which is found in large quantities in the blood of men with prostate cancer, is also produced by women with breast tumors. Findings of researchers in Toronto Hospital, Ont. and Jefferson Cancer Center in Philadelphia, Pa.;...

  • Autophagy in Prostate Cancer and Androgen Suppression Therapy. Ziparo, Elio; Petrungaro, Simonetta; Marini, Elettra Sara; Starace, Donatella; Conti, Silvia; Facchiano, Antonio; Filippini, Antonio; Giampietri, Claudia // International Journal of Molecular Sciences;Jun2013, Vol. 14 Issue 6, p12090 

    The role of autophagy is known to be highly complex and context-dependent, leading to both cancer suppression and progression in several tumors including melanoma, breast and prostate cancer. In the present review, recent advances in an understanding of the involvement of autophagy in prostate...

  • Does Androgen Deprivation Improve Outcomes for Localized Prostate Cancer?  // Neurology Alert;Oct2011 Pharmacology, p20 

    The article discusses research treatment for prostate cancer, referencing a study in the "New England Journal of Medicine," which found that treatment with androgen-deprivation in the short-term improves results in men with localized prostate cancer.

  • Evaluate PSA rise, hormone restoration post-IAD. Guttman, Cheryl // Urology Times;Jun2000, Vol. 28 Issue 6, p6 

    Details findings of a study, conducted by researchers at the University of Michigan and presented at the American Urological Association (AUA) annual meeting, which recommended that the evaluation of prostate specific antigen (PSA) response in patients treated with interrupted androgen...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics